By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Five biopharma company CEOs answered our questions and contributed their thoughts for this article. The companies — Locanabio, BridGene, MorphImmune, Seismic Therapeutic, and Tubulis — all invented their own technology platforms and have since used them to create their own pipelines for development. Having looked at the sequence and significance of the steps each company has taken in that transition, we continue here with views of their future plans, as well as their leaders’ observations of the platform-to-pipeline space they are effectively expanding, by joining a gathering crowd of companies now entering it.